BR0011880A - Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica - Google Patents
Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêuticaInfo
- Publication number
- BR0011880A BR0011880A BR0011880-0A BR0011880A BR0011880A BR 0011880 A BR0011880 A BR 0011880A BR 0011880 A BR0011880 A BR 0011880A BR 0011880 A BR0011880 A BR 0011880A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treatment
- obesity
- conditions associated
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"MéTODO PARA O TRATAMENTO DE CONDIçõES CO-MóRBIDAS ASSOCIADAS COM OBESIDADE, COMPOSTO , PRODUTO, USO DE UM COMPOSTO, E, COMPOSIçãO FARMACêUTICA". Método para o tratamento de condições co-mórbidas associadas com obesidade em humanos necessitados de tal tratamento que compreende administração ao humano de quantidade terapeuticamente efetiva do composto de fórmula (I): que inclui enanciómeros e sais farmaceuticamente aceitáveis dos mesmos, em que R~ 1~ e R~ 2~ são independentemente H ou metila, e quantidade terapeuticamente efetiva do composto de fórmula (II) em que o composto de fórmula (I) e o composto de fórmula (II): são administrados simultaneamente, separadamente ou seq³encialmente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9914744.9A GB9914744D0 (en) | 1999-06-24 | 1999-06-24 | Therapeutic agents |
PCT/EP2000/005542 WO2001000205A1 (en) | 1999-06-24 | 2000-06-16 | Pharmaceutical composition containing sibutramine and orlistat |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0011880A true BR0011880A (pt) | 2002-03-19 |
Family
ID=10855955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0011880-0A BR0011880A (pt) | 1999-06-24 | 2000-06-16 | Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1187606A1 (pt) |
JP (1) | JP2003503349A (pt) |
KR (1) | KR20020015357A (pt) |
CN (1) | CN1358092A (pt) |
AU (1) | AU5533200A (pt) |
BG (1) | BG106180A (pt) |
BR (1) | BR0011880A (pt) |
CA (1) | CA2375972A1 (pt) |
CZ (1) | CZ20014613A3 (pt) |
GB (1) | GB9914744D0 (pt) |
HK (1) | HK1049278A1 (pt) |
HU (1) | HUP0201878A3 (pt) |
IL (1) | IL147079A0 (pt) |
MX (1) | MXPA01012936A (pt) |
NO (1) | NO20016224L (pt) |
PL (1) | PL352402A1 (pt) |
RU (1) | RU2229289C2 (pt) |
SK (1) | SK18242001A3 (pt) |
TR (1) | TR200103699T2 (pt) |
WO (1) | WO2001000205A1 (pt) |
ZA (1) | ZA200109989B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696495B2 (en) * | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
EP1807063A2 (en) | 2004-10-25 | 2007-07-18 | Solvay Pharmaceuticals GmbH | Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
AU2007296074B2 (en) | 2006-09-15 | 2012-07-12 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cycloalkylmethylamines |
US20100099773A1 (en) * | 2006-11-22 | 2010-04-22 | Jae-Sun Kim | Inclusion complex of sibutramine and beta-cyclodextrin |
CN101890017A (zh) * | 2009-05-22 | 2010-11-24 | 北京奥萨医药研究中心有限公司 | 含有西布曲明和他汀类降脂药物的药物组合物及其用途 |
WO2012003501A2 (en) | 2010-07-02 | 2012-01-05 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
MX336980B (es) | 2010-12-21 | 2016-02-09 | Senosiain S A De C V Lab | Combinacion y composicion para el tratamiento de obesidad. |
UA114807C2 (uk) | 2011-12-30 | 2017-08-10 | Ревіва Фармасьютікалс, Інк. | Композиції, синтез і способи застосування похідних фенілциклоалкілметиламіну |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9727131D0 (en) * | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
-
1999
- 1999-06-24 GB GBGB9914744.9A patent/GB9914744D0/en not_active Ceased
-
2000
- 2000-06-16 PL PL00352402A patent/PL352402A1/xx not_active Application Discontinuation
- 2000-06-16 AU AU55332/00A patent/AU5533200A/en not_active Abandoned
- 2000-06-16 WO PCT/EP2000/005542 patent/WO2001000205A1/en not_active Application Discontinuation
- 2000-06-16 MX MXPA01012936A patent/MXPA01012936A/es unknown
- 2000-06-16 CA CA002375972A patent/CA2375972A1/en not_active Abandoned
- 2000-06-16 IL IL14707900A patent/IL147079A0/xx unknown
- 2000-06-16 EP EP00940379A patent/EP1187606A1/en not_active Withdrawn
- 2000-06-16 RU RU2002102076/14A patent/RU2229289C2/ru not_active IP Right Cessation
- 2000-06-16 TR TR2001/03699T patent/TR200103699T2/xx unknown
- 2000-06-16 KR KR1020017016575A patent/KR20020015357A/ko not_active Application Discontinuation
- 2000-06-16 BR BR0011880-0A patent/BR0011880A/pt not_active IP Right Cessation
- 2000-06-16 HU HU0201878A patent/HUP0201878A3/hu unknown
- 2000-06-16 CZ CZ20014613A patent/CZ20014613A3/cs unknown
- 2000-06-16 CN CN00809372A patent/CN1358092A/zh active Pending
- 2000-06-16 SK SK1824-2001A patent/SK18242001A3/sk unknown
- 2000-06-16 JP JP2001505914A patent/JP2003503349A/ja active Pending
-
2001
- 2001-12-04 BG BG106180A patent/BG106180A/xx unknown
- 2001-12-05 ZA ZA200109989A patent/ZA200109989B/xx unknown
- 2001-12-19 NO NO20016224A patent/NO20016224L/no not_active Application Discontinuation
-
2003
- 2003-01-09 HK HK03100246.9A patent/HK1049278A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CZ20014613A3 (cs) | 2003-04-16 |
GB9914744D0 (en) | 1999-08-25 |
NO20016224D0 (no) | 2001-12-19 |
NO20016224L (no) | 2002-02-12 |
MXPA01012936A (es) | 2004-04-21 |
TR200103699T2 (tr) | 2002-04-22 |
PL352402A1 (en) | 2003-08-25 |
ZA200109989B (en) | 2003-02-26 |
CA2375972A1 (en) | 2001-01-04 |
HUP0201878A3 (en) | 2005-04-28 |
SK18242001A3 (sk) | 2003-02-04 |
HK1049278A1 (zh) | 2003-05-09 |
KR20020015357A (ko) | 2002-02-27 |
IL147079A0 (en) | 2002-08-14 |
CN1358092A (zh) | 2002-07-10 |
WO2001000205A1 (en) | 2001-01-04 |
RU2229289C2 (ru) | 2004-05-27 |
HUP0201878A2 (hu) | 2003-08-28 |
AU5533200A (en) | 2001-01-31 |
JP2003503349A (ja) | 2003-01-28 |
EP1187606A1 (en) | 2002-03-20 |
BG106180A (en) | 2002-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
BR0012590A (pt) | Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central | |
EP1428821A8 (en) | Piperidin-4-yl amines with analgesic effect | |
GEP20043324B (en) | Purine Derivatives | |
BR0000003A (pt) | Azalidas e métodos de preparação das mesmas | |
CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
TR199801180T2 (xx) | Aneljestik etkiye sahip yeni bile�ikler. | |
MY119403A (en) | Novel compounds with analgesic effect. | |
BR0113496A (pt) | Composto ou um sal farmaceuticamente aceitável ou ester hidrolisável in vivo deste, uso destes, método para produzir um efeito inibidor do ciclo celular (anti-proliferação celular) em um animal de sangue quente, e, composição farmacêutica | |
BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
DK0503440T3 (da) | Sumatriptanholdige lægemidler | |
GEP20002298B (en) | Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment | |
BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
BR0010938A (pt) | Derivados da 13-metil eritromicina | |
SE9900961D0 (sv) | Novel compounds | |
BR9814498A (pt) | Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica | |
BR9813319A (pt) | Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto | |
BR9915480A (pt) | Azalìdeos de 13 membros e a sua utilização como agentes antibióticos | |
BR0012610A (pt) | Novo derivado de difenilpiperidina | |
BR0011880A (pt) | Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica | |
BR0007452A (pt) | Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação | |
GEP20043227B (en) | 5HT1 Antagonists for Antidepressant Therapy | |
BR0011884A (pt) | Método de tratamento da obesidade e condições comórbidas em um ser humano necessitando de tal tratamento, composto da fórmula i, produto contendo o composto da fórmula i, uso do composto da fórmula i, e, composição farmacêutica | |
GEP20043231B (en) | Resorcinol Composition | |
AP9801235A0 (en) | Erythromycin derivatives. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer |
Owner name: ABBOTT GMBH & CO. KG (DE) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled | ||
B25A | Requested transfer of rights approved |
Free format text: ABBOTT GMBH (DE) |
|
B25D | Requested change of name of applicant approved | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |